Our results suggested that for AML patients with both GLI1 and AKT activation, the GLI1 inhibitor alone is sufficient, which will significantly decrease the unnecessary side effects of the combination therapy using Hh and PI3K inhibitors. The gene discussed is GLI1; the disease is acute myeloid leukemia.